The process involves comparing the results of the new imaging method with standard ways of checking how well the liver is working. These existing methods include the indocyanine green clearance test, which measures how the liver processes a specific dye, and various scoring systems like the Child-Pugh score and the MELD score used to assess liver health. Additionally, ultrasound elastography, a non-invasive way to check the stiffness of the liver, may be used. By comparing these different tools, the study seeks to find the most accurate way to identify patients who might face complications after their surgery.

The treatment involves injecting Giapreza into the blood vessels that supply the liver tumors, followed by the delivery of radioactive glass microspheres. The medication is given as a solution that is injected into the artery at a specific dose over a brief period. This combined approach aims to improve how well the radiation treatment reaches the tumor tissue compared to surrounding healthy liver tissue.

During the study, participants will receive Giapreza through an artery leading to the liver, immediately followed by the standard radioembolization treatment. Special imaging techniques called PET/CT and SPECT/CT scans will be used to evaluate how effectively the treatment reaches the tumor. The study will also monitor the safety of combining these two treatments.

The study aims to improve the detection of liver tumors by using a combination of these imaging techniques and the glowing effect of Indocyanine Green. Additionally, researchers are working on developing a computer program that uses machine learning to analyze photographs of the liver during surgery to help identify tumors. This program will be trained to recognize patterns in the images that indicate the presence of tumors, potentially making it easier for surgeons to find and remove them.

Participants in the study will receive the Indocyanine Green injection before their surgery. During the operation, doctors will use the special light and imaging techniques to locate the tumors. The study will help determine how effective this method is in finding liver tumors during surgery. The trial is expected to continue until early 2027, with recruitment starting in early 2024.

The purpose of the study is to explore how digital health solutions can impact health outcomes and the use of healthcare resources for people receiving systemic treatment, which is a type of treatment that affects the entire body. In the first group, the study aims to show how a digital patient monitoring system can help manage symptoms for those receiving atezolizumab. In the second group, the study will look at how feasible it is to combine this digital monitoring with atezolizumab treatment administered at home.

Participants in the study will receive either atezolizumab or a placebo. The study will monitor various aspects of health, including symptom management and the number of hospital visits. The trial will also assess the safety and side effects of atezolizumab when used in combination with digital health tools. The study is expected to continue until 2025, with participants being observed over a period of time to gather comprehensive data on the treatment’s effectiveness and impact on quality of life.

The purpose of this study is to evaluate the safety and effectiveness of these medications when used together. Participants in the study will receive the combination of these medications and will be monitored for any side effects and how their cancer responds to the treatment. The study will take place over a period of time, during which participants will have regular check-ups and assessments to track their progress. The study aims to understand how well the combination of these medications can help in treating the different types of cancer mentioned.

Throughout the study, participants will be closely observed to ensure their safety and to gather information on how the treatment affects their cancer. The study will help researchers learn more about the potential benefits and risks of using Pembrolizumab, Lenvatinib, and Belzutifan together, which could lead to new treatment options for patients with these types of cancer in the future.

Participants in the study will be divided into two groups. One group will receive the combination of Atezolizumab and Bevacizumab, while the other group will receive all three medications, including Ipilimumab. The study will last for a period of up to 24 months, during which the effects of the treatments will be monitored. The main goal is to see if the addition of Ipilimumab can help improve the overall survival of patients compared to the two-drug combination. The study will also look at how well the cancer responds to the treatments and how long patients can live without the disease getting worse.

Throughout the study, participants will receive regular check-ups to monitor their health and the progress of their cancer. The study aims to provide valuable information on whether the addition of Ipilimumab offers a significant benefit in treating hepatocellular carcinoma. Participants will be closely observed for any side effects or changes in their quality of life during the treatment period. This research could potentially lead to improved treatment options for patients with this type of liver cancer.

The study will be conducted in two parts. In the first part, participants with advanced solid tumors will receive the combination of cobolimab and dostarlimab to assess safety and determine the appropriate dosage. In the second part, the study will focus on specific types of cancer, including melanoma and Hodgkin lymphoma, to evaluate the effectiveness of the treatment. Participants will receive the medications through an intravenous infusion, which means the medicine is given directly into a vein.

Throughout the study, participants will be closely monitored for any side effects and changes in their health. The trial will help researchers gather important information about the potential benefits and risks of using cobolimab and dostarlimab together in treating these challenging conditions. The study is expected to continue until 2030, providing valuable insights into new treatment options for young patients with difficult-to-treat tumors.

Participants in the study will receive both pembrolizumab and lenvatinib. The study will observe how the cancer responds to this combination of treatments. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects. The study will last for a period of up to 24 months, during which participants will be monitored regularly to assess the response of their cancer to the treatment. The study aims to determine the effectiveness of the treatment by measuring the rate at which the cancer shrinks or disappears, known as the objective response rate.

Throughout the study, participants will undergo various assessments to monitor their health and the progression of their cancer. These assessments may include imaging tests like MRI or CT scans to measure the size of the cancer. The study will also track the overall survival of participants and any side effects they may experience. The goal is to gather information that could lead to better treatment options for patients with advanced stage hepatocellular carcinoma who have not responded to previous therapies.